Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned

Cullinan Therapeutics, Inc.

Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.
Decision based on not pursuing further development of CLN-617 cancer immunotherapy.
Company will return licensed patent rights for CLN-617 technology to MIT.
CLN-617 was an exclusive worldwide license for a cancer immunotherapy product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.